|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.40 CHF | +0.27% |
|
+0.67% | -12.51% |
| Oct. 25 | BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 | CI |
| Oct. 25 | BB Biotech's Q3 Loss Widens; Operating Income Drops | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 2.05B 2.31B 2.2B 1.82B 3.25B 195B 3.56B 25.43B 9.43B 80.17B 8.67B 8.48B 345B | P/E ratio 2024 * |
9.71x | P/E ratio 2025 * | 8.88x |
|---|---|---|---|---|---|
| Enterprise value | 2.29B 2.59B 2.46B 2.04B 3.64B 219B 3.99B 28.5B 10.57B 89.85B 9.72B 9.5B 387B | EV / Sales 2024 * |
9.2x | EV / Sales 2025 * | 7.94x |
| Free-Float |
97.2% | Yield 2024 * |
6.38% | Yield 2025 * | 6.49% |
More valuation ratios
* Estimated data
More news
More press releases
| 1 day | +0.34% | ||
| 1 week | +0.40% | ||
| Current month | -0.13% | ||
| 1 month | +1.22% | ||
| 3 months | -1.71% | ||
| 6 months | -7.33% | ||
| Current year | -12.75% |
1 week
36.90
37.90
1 month
35.5540.20
Current year
35.4549.80
1 year
35.4549.80
3 years
35.3578.80
5 years
35.3593.45
10 years
35.3593.45
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Koller
CEO | Chief Executive Officer | 54 | 2013-02-24 |
Felicia Flanigan
PRN | Corporate Officer/Principal | - | 2010-11-16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Clive Meanwell
BRD | Director/Board Member | 67 | 2003-12-31 |
| Chairman | 63 | 2024-03-20 | |
| Director/Board Member | 64 | 2019-12-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.34% | +0.40% | -0.67% | -49.76% | 2.31B | ||
| +0.13% | +1.70% | +59.29% | -25.55% | 42.79B | ||
| -0.60% | -0.32% | -7.53% | -23.35% | 36.41B | ||
| +1.25% | +6.44% | +14.59% | -5.81% | 27.1B | ||
| -0.27% | +0.40% | -20.92% | -21.93% | 17.58B | ||
| -3.80% | +1.26% | -46.66% | -86.12% | 16.39B | ||
| -0.36% | -2.18% | +53.20% | +98.28% | 16.46B | ||
| -1.28% | +0.24% | +16.23% | -34.19% | 11.92B | ||
| -0.90% | +1.21% | +23.19% | +64.58% | 10.52B | ||
| -0.97% | +0.78% | -1.18% | -44.23% | 10.19B | ||
| Average | -0.08% | +0.46% | +8.95% | -12.81% | 19.17B | |
| Weighted average by Cap. | +0.11% | +0.45% | +14.74% | -13.42% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 249M 281M 267M 222M 395M 23.8B 434M 3.1B 1.15B 9.76B 1.06B 1.03B 42.01B | 268M 303M 288M 239M 426M 25.67B 468M 3.34B 1.24B 10.53B 1.14B 1.11B 45.3B |
| Net income | 203M 229M 218M 181M 323M 19.44B 354M 2.53B 937M 7.97B 862M 843M 34.31B | 166M 187M 178M 148M 264M 15.88B 289M 2.07B 766M 6.51B 704M 689M 28.03B |
| Net Debt | 247M 279M 265M 220M 392M 23.61B 430M 3.07B 1.14B 9.68B 1.05B 1.02B 41.68B | 86.1M 97.17M 92.43M 76.75M 137M 8.23B 150M 1.07B 397M 3.38B 365M 357M 14.53B |
More financial data
* Estimated data
Employees
10
Calendar
2025-02-21
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-04 | 37.40 CHF | +0.27% | 78,550 |
| 24-12-03 | 37.30 CHF | -0.67% | 54,224 |
| 24-12-02 | 37.55 CHF | +0.54% | 104,866 |
| 24-11-29 | 37.35 CHF | 0.00% | 61,745 |
| 24-11-28 | 37.35 CHF | +0.54% | 42,899 |
Delayed Quote Swiss Exchange, December 04, 2024 at 05:03 am EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
37.30CHF
Average target price
55.85CHF
Spread / Average Target
+49.73%
Annual profits - Rate of surprise
- Stock Market
- Equities
- BION Stock